Sign In
Buy IVVD
$1.10
-0.0400 (-3.51%)
At Close: Jun 03, 2026
Adagio Therapeutics CEO: We see a role in the treatment of Covid, as well as prevention
05:22pm, Monday, 29'th Nov 2021
Tillman Gerngross, Adagio Therapeutics CEO, joins 'The Exchange' to discuss how his company's antibody drug was developed and its effectiveness in fighting Covid variants.
Morgan Stanley: Omicron will benefit this relatively new biotech firm
05:18pm, Monday, 29'th Nov 2021
Adagio Therapeutics Inc (NASDAQ: ADGI) was up more than 75% on Monday after the biotech firm said Omicron was unlikely to be more resistant against its investigational monoclonal antibody, ADG20, desp
4 Top Biotech Stocks To Watch Now
05:07pm, Monday, 29'th Nov 2021
With all eyes on the pandemic once again, these biotech players could be gaining more exposure.
ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential
04:57pm, Monday, 29'th Nov 2021
Shares of ADGI stock are soaring higher by 80% after the company stated that its ADG-20 antibody is effective against the omicron variant. The post ADGI Stock Soars as Analysts Lock On to Its Omicron-
Adagio Therapeutics (ADGI) Stock: Why The Price Surged Today
08:43am, Monday, 29'th Nov 2021
The stock price of Adagio Therapeutics Inc (NASDAQ: ADGI) increased by over 25% pre-market today. This is why it happened.
Adagio Therapeutics to Participate in Upcoming Investor Conferences
06:30am, Wednesday, 10'th Nov 2021
WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of an
Data to be presented at the 2021 ISIRV-WHO Virtual Conference Data to be presented at the 2021 ISIRV-WHO Virtual Conference
Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months
09:33am, Wednesday, 29'th Sep 2021
Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new data from its COVID-19 antibody program. Related Link: Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial.
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
06:30am, Wednesday, 29'th Sep 2021
ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study
New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021
Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial
11:13am, Friday, 10'th Sep 2021
Adagio Therapeutics Inc (NASDAQ: ADGI) announced that the independent data monitoring committee (IDMC) has recommended expanding the ADG20 EVADE Phase 2/3 trial for COVID-19. The IDMC has supported
3 Biotech Stocks That Soared to New Heights Last Week
06:21am, Sunday, 05'th Sep 2021
Find out what these industry favorites are doing to impress investors.
DoubleDown Interactive Makes Its Market Debut, Wrapping Up a Slow Month for IPOs
02:05pm, Tuesday, 31'st Aug 2021
The Korean gaming company is one of 10 companies that have gone public in August using a traditional initial public offering, Dealogic said.
U.S. IPO Weekly Recap: Postponements Abound In A 4 IPO Week
12:06am, Saturday, 07'th Aug 2021
U.S. IPO Weekly Recap: Postponements Abound In A 4 IPO Week
Adagio Therapeutics' upsized IPO prices in middle of range, valued company at more than $1.8 billion
06:22am, Friday, 06'th Aug 2021
Adagio Therapeutics Inc. is set to go public Friday, after the upsized initial public offering of the Massachusetts-based biopharmaceutical company focused on antibody-based solutions for infectious d
